Synthesis and Evaluation of 17α-Arylestradiols as Ligands for Estrogen Receptor α and β
摘要:
To identify novel estrogen receptor ligands a series of substituted 17 alpha-arylestradiols were synthesized using the catalytic [2 + 2 + 2]cyclotrimerization of 17 alpha-ethynylestradiol with various 1,7-diynes in the presence of Wilkinson's catalysts [Rh(PPH3)(3)Cl]. The compounds were subjected to competitive binding assays, cell-based luciferase reporter assays, and proliferation assays. These experiments confirmed their estrogenic character and revealed some interesting properties like mixed partial/full agonism for ER alpha/ ER beta and different selectivity as a result of differing potencies for either ER.
[EN] LIGANDS OF ESTROGEN RECEPTORS a AND ß, METHOD OF THEIR PREPARATION AND PHARMACEUTICALS COMPRISING THEM<br/>[FR] LIGANDS DES RÉCEPTEURS DES OESTROGÈNES a ET ß, PROCÉDÉ DE PRÉPARATION ET PRODUITS PHARMACEUTIQUES COMPRENANT LESDITS LIGANDS
申请人:USTAV MOLEKULARNI GENETIKY AV
公开号:WO2009135449A1
公开(公告)日:2009-11-12
The invention relates to novel ligands of the estrogen receptors α and β of general formula (II), which are useful as active substance of pharmaceuticals, for example pharmaceutical compositions useful for hormone replacement therapy, as well as for the treatment of tumour and inflammatory diseases. The invention relates also to a novel preparation method of these ligands comprising cyclotrimerization of ethynylestradiol with the appropriate diyne in an organic solvent. Further, the invention relates to pharmaceuticals comprising the novel compounds according to the invention.
Ligands of Estrogen Receptors alpha and beta, Method of Their Preparation, and Pharmaceuticals Comprising Them
申请人:Novak Petr
公开号:US20110118225A1
公开(公告)日:2011-05-19
The invention relates to novel ligands of the estrogen receptors α and β of general formula II, which are useful as an active substance of pharmaceuticals, for example pharmaceutical compositions useful for hormone replacement therapy, as well as for the treatment of tumors and inflammatory diseases. The invention also relates to a novel preparation method of these ligands comprising cyclotrimerization of ethynylestradiol with the appropriate diyne in an organic solvent. Further, the invention relates to pharmaceuticals comprising the novel compounds according to the invention.
To identify novel estrogen receptor ligands a series of substituted 17 alpha-arylestradiols were synthesized using the catalytic [2 + 2 + 2]cyclotrimerization of 17 alpha-ethynylestradiol with various 1,7-diynes in the presence of Wilkinson's catalysts [Rh(PPH3)(3)Cl]. The compounds were subjected to competitive binding assays, cell-based luciferase reporter assays, and proliferation assays. These experiments confirmed their estrogenic character and revealed some interesting properties like mixed partial/full agonism for ER alpha/ ER beta and different selectivity as a result of differing potencies for either ER.